Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03700892 · ClinicalTrials.gov registry record · NA
In-vivo Effects of E-cigarette Aerosol on Innate Lung Host Defense
A NA study, sponsored by University of North Carolina, Chapel Hill.
- Terminated
- Registry status
- NA
- Development phase
- 19
- Enrollment target
NCT03700892 is a NA study that was terminated before completion, run by University of North Carolina, Chapel Hill. The registered enrollment target is 19 participants.
The verdict
NCT03700892, a NA study, was terminated before completion, sponsored by University of North Carolina, Chapel Hill.
- TERMINATED
- Registry status
- NA
- Development phase
- 19 participants
- Enrollment target
Study Summary
While e-cigs are commonly represented as safer alternatives to tobacco cigarettes, little is known regarding the health effects of their short- or long-term use. The responses and the e-cig components exerting these effects on the airways are largely unknown. This study will identify if specific e-cig flavors modify respiratory immune responses. This study will determine the effects of cinnamaldehyde (CA)-containing e-cigarettes on airway epithelial cell ciliary function (i.e., MCC) in humans. Additionally the study will determine the effects of CA-containing e-cigarettes on airway immune cells obtained through induced sputum (SI) after inhalation of CA-containing e-cig aerosols to determine CA-induced effects on a) immune cell function (e.g., phagocytosis, respiratory burst), b) immune cell surface phenotype, and c) mediator production in humans in vivo.
Interventions
- OTHER Cinnamaldehyde e-liquid
- OTHER PG/VG e-liquid
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 19 participants |
| Start Date | 2018-10-19 |
| Est. Completion | 2020-03-03 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03700892
The ClinicalTrials.gov registry entry for NCT03700892 describes a study currently listed as terminated, categorized as NA. The registered enrollment target is 19 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of North Carolina, Chapel Hill, which has 1,109 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Cinnamaldehyde e-liquid is the first listed.
NCT03700892 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03700892 about?
NCT03700892 is a clinical study titled "In-vivo Effects of E-cigarette Aerosol on Innate Lung Host Defense". While e-cigs are commonly represented as safer alternatives to tobacco cigarettes, little is known regarding the health effects of their short- or long-term use. The responses and the e-cig components exerting these effects on the airways are largely unknown. This study will identify if specific e-c...
What is the current status of trial NCT03700892?
This trial is currently terminated. It is a NA study. The enrollment target is 19 participants. The study started on 2018-10-19. Estimated completion is 2020-03-03.
What interventions are being tested in trial NCT03700892?
The interventions under investigation include: Cinnamaldehyde e-liquid (OTHER), PG/VG e-liquid (OTHER).
Who is sponsoring clinical trial NCT03700892?
This trial is sponsored by University of North Carolina, Chapel Hill, which has 1,109 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.